Efficacy of acupuncture and medicine in the treatment of climacteric hypertension with liver-kidney yin deficiency
针药治疗肝肾阴虚型更年期高血压的疗效

摘要

目的 谈论针药联合医治对于肝肾阴虚型更年期高血压患者的病情恢复影响。方法 此次研究对象筛取2019年1月到2021年12月期间笔者所在社区卫生服务中心收治的肝肾阴虚型更年期高血压病人，契合选入与排除准则的95例，依照医治方案的不同归为两个小组，对照组（n=47，实行药物医治）与实验组（n=48，在前者的基础上采用针刺疗法）。分析两小组病人的医治疗效详情、血压状况及症状改善。结果 实验组病人的医治疗效（97.92%）得到显著提升且优于对照组（91.49%）；实验组病人经医治后的收缩压、舒张压得到显著降低且优于对照组；实验组病人经医治后的头晕目眩、潮热失眠、腰膝酸软、急躁易怒症状改善十分明显且优于对照组，组间存在显著差异用P＜0.05表明，具有统计学价值。结论 对肝肾阴虚型更年期高血压患者实行针药联合医治方案，医治效果达到理想预期值，病情症状得到理想改善，值得增大临床推广范围。

Abstract

Objective: To discuss the effect of combined acupuncture and medicine on the recovery of climacteric hypertension patients with liver-kidney yin deficiency.
Methods: In this study, 95 patients with climacteric hypertension with liver and kidney yin deficiency who were admitted to the author's community health service center from January 2019 to December 2021 were screened, and 95 cases met the inclusion and exclusion criteria. The patients were divided into two groups, the control group (n=47, who practiced drug treatment) and the experimental group (n=48, who used acupuncture therapy on the basis of the former). The details of medical treatment efficacy, blood pressure status and symptom improvement of the patients in the two groups were analyzed.
Results: The medical treatment effect of the patients in the experimental group (97.92%) was significantly improved and better than that of the control group (91.49%). After treatment, the symptoms of dizziness, hot flashes, insomnia, weak waist and knees, irritability and irritability were significantly improved and better than those of the control group. P<0.05 indicated that there was a significant difference between the groups, which was of statistical value.
Conclusion  : The combined acupuncture and medicine treatment program for climacteric hypertension patients with liver-kidney yin deficiency can achieve the desired therapeutic effect, and the symptoms of the disease can be improved ideally, which is worthy of increasing the scope of clinical promotion.